WSWilliam Schaffner

William Schaffner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William Schaffner has a total of 301 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Trends in Mortality and the Effects of the Coronavirus Disease 2019 Pandemic on Mortality Among Adult Patients With Staphylococcus aureus Bacteremia, 20 US Counties, 2005–2022

    by Carly Adams, Holly M Biggs, Kelly A Jackson, Joelle Nadle, Susan Petit, Susan M Ray, Ruth Lynfield, Carmen Bernu, Ghinwa Dumyati, Marissa Walsh, et al.

    Background: Trends in Staphylococcus aureus bacteremia (SAB) mortality in the United States, including the impact of coronavirus disease 2019, have not been well described. Methods: Active, laboratory- and population-based surveillance data from 20 counties (7 states) were used to examine annual, 30-day mortality rates among US adult patients with methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA and MSSA, respectively) bacteremia during 2005–2022. Medical records and state vital statistics data were linked to ascertain death. Multivariable survival analysis estimated the association between recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (a positive SARS-CoV-2 test of ≤30 days before incident culture) and mortality among SAB cases, adjusting for other risk factors. Analyses were stratified by MRSA/MSSA and epidemiologic class (hospital-onset [HO], healthcare-associated community-onset [HACO], and community-associated [CA]). Results: Overall, SAB mortality was 21%. Annual SAB mortality rates were generally stable prepandemic before increasing by 33% and 41% among HO MRSA and MSSA cases, respectively, and by 49% among CA MRSA cases, but not among HACO or MSSA CA cases, from 2019 through 2021. Among HO cases with recent SARS-CoV-2 infection, annual mortality rates were as high as 75%. Adjusted hazard ratios for recent SARS-CoV-2 infection ranged from 1.9 (95% confidence interval: 1.5–2.3) (HACO MRSA) to 3.0 (95% confidence interval: 2.4–3.7) (HO MSSA). Conclusions: Recent SARS-CoV-2 infection was a significant risk factor for death among patients with SAB during 2020–2022. Strengthening infection prevention efforts in similar respiratory pandemics in the future could help prevent increases in SAB mortality rates.

  • Prevalence and Outcomes of Bacterial Co-detections by Blood Culture Among Children and Adults Hospitalized With Laboratory-confirmed Influenza, Influenza Hospitalization Surveillance Network, 2022–2024

    by Mark W Tenforde, Dawud Ujamaa, H Keipp Talbot, Alissa C O’HAlloran, Shua J Chai, Darpun Sachdev, Isaac Armistead, Nisha B Alden, James Meek, Kimberly Yousey-Hindes, et al.

    Background: Influenza predisposes individuals to bacterial co-infections, which can result in disseminated infection and bacteremia. We describe the epidemiology and outcomes of blood culture co-detections among those hospitalized with influenza over 2 influenza seasons. Methods: We sampled individuals of all ages from FluSurv-NET, a US population–based surveillance network of persons hospitalized with laboratory-confirmed influenza, during the 2022–2023 and 2023–2024 seasons. Surveillance staff collected information on bacterial blood cultures within 3 days before or 3 days following admission. We described patient characteristics and in-hospital outcomes, stratified by culture positivity, number of positive cultures, and type of co-detection, using unweighted counts and weighted percentages to account for the complex survey design. Results: Overall, 14 316 patients were included, with a median (interquartile range) age of 57 (14–74) years, 53.6% female, 52.0% non-Hispanic White, and 25.6% with ≥4 categories of underlying medical conditions. Of these, 50.8% had ≥1 blood cultures obtained and 5.2% overall had ≥1 bacterial co-detections. Intensive care unit admission occurred for 9.6%, 19.2%, 31.2%, and 47.9% among patients with no blood cultures, negative cultures, 1 co-detection, and >1 co-detection documented, respectively; in-hospital mortality occurred in 1.5%, 3.3%, 9.4%, and 14.5%, respectively. Among patients with positive cultures, 22.1% had Staphylococcus aureus and 7.5% had Streptococcus pneumoniae co-detections; both were associated with severe illness (with 22.4% in-hospital mortality each). Discussion: Bacterial co-detections in persons hospitalized with influenza were associated with poor in-hospital outcomes. Efforts to prevent severe influenza and bacterial co-infections, including through vaccination, may reduce substantial morbidity and mortality from influenza.


  • Epidemiology of Pediatric Invasive Group A Streptococcal Infections in 10 U.S. States, 2004–2023

    by Veena Ramachandran, Jennifer Onukwube Okaro, Namrata Prasad, Soyoun Park, Lesley McGee, Sopio Chochua, Yuan Li, Bridget J Anderson, Kari E Burzlaff, Lee H Harrison, et al.

    Background: Group A Streptococcus (GAS) infections are common in children, ranging from mild to life-threatening invasive disease. Large-scale descriptions of changes in pediatric invasive GAS infections in the United States, particularly during the COVID-19 pandemic, are limited. Methods: We used CDC’s Active Bacterial Core surveillance (ABCs), a multistate, population- and laboratory-based surveillance system, to assess changes in pediatric (<18 years old) invasive GAS incidence, clinical presentation, and bacterial strain characteristics from 2004–2023. Interrupted time series analysis was used to compare observed versus expected GAS incidence during 2020–2023, informed by trends before the COVID-19 pandemic (2004–2019). Results: During 2004–2023, 2,856 invasive GAS cases were identified. Incidence remained stable from 2004–2019 (mean incidence 1.9 per 100,000), decreased in 2020 (1.0) and 2021 (0.6), and rebounded in 2022 (1.5) and 2023 (4.4). ICU admission increased from 2011 to 2023; case fatality remained stable. Penicillin resistance was not detected. Clindamycin non-susceptibility doubled from 2011 (3.8%) to 2022 (7.5%), before slightly decreasing in 2023 (6.4%). Infections due to emm1, the most frequently identified emm type in children with severe disease, almost disappeared in 2021 but surged in late 2022. Conclusions: After remaining stable for more than a decade, pediatric invasive GAS incidence declined during the COVID-19 pandemic and rebounded in 2022, more than doubling 2004–2019 incidence in 2023. While case fatality remained low, ICU admissions increased over time, highlighting the need for effective preventive measures such as vaccines. Increasing clindamycin non-susceptibility bears continued monitoring.


  • Effects of Age and Birth Cohort on Influenza A Virus Subtype-Specific Hospitalization Rates, United States, 2010–2025

    by Alissa O’HAlloran, Nicole Hood, Dawud Ujamaa, Angiezel Merced-Morales, Brian Gurbaxani, Pam Daily Kirley, Monica J Napoles, Nisha B Alden, Deborah Aragon, James Meek, et al.

    Background: Older individuals (≥65 years) are at greatest risk of severe influenza requiring hospitalization. Since 2009, influenza-associated hospitalization rates during A(H1N1)pdm09-predominant influenza seasons have been lower than during A(H3N2)-predominant seasons. Methods: Using laboratory-confirmed influenza hospitalization rates from US population–based surveillance, we investigated the relative A(H1N1)pdm09 to A(H3N2) hospitalization rate ratios by patient year of age and birth cohort from 2010 through 2025. Results: Results suggest partial protection against A(H1N1)pdm09 hospitalizations relative to A(H3N2) hospitalizations among patients born before 1945 (pre-1945 birth cohorts) and among individuals born during 1994 through 2009. Impact of partial protection against A(H1N1)pdm09-associated hospitalizations has diminished over time among older adults, contributing to elevated influenza hospitalization rates during the 2024–2025 influenza season. Conclusions: Our findings suggest that influenza A hospitalization rates may increase during future influenza seasons when influenza A(H3N2) and A(H1N1) viruses circulate or following the emergence of novel A(H1N1)pdm09-like viruses.

  • Impact of Serotype Uncertainty on Adult Pneumococcal Vaccine Options: A Value of Information Analysis

    by Angela R. Wateska, Shoroq M. Altawalbeh, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith


  • Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulations

    by Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Shoroq M. Altawalbeh, Richard K. Zimmerman


  • Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older

    by Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith


  • Open Access

    Respiratory syncytial virus: an under-recognized healthcare-associated infection

    by Erin B. Gettler, H. Keipp Talbot, Yuwei Zhu, Danielle Ndi, Edward Mitchel, Tiffanie M. Markus, William Schaffner, Bryan Harris, Thomas R. Talbot

    Objective: Prior reports of healthcare-associated respiratory syncytial virus (RSV) have been limited to cases diagnosed after the third day of hospitalization. The omission of other healthcare settings where RSV transmission may occur underestimates the true incidence of healthcare-associated RSV. Design: Retrospective cross-sectional study. Setting: United States RSV Hospitalization Surveillance Network (RSV-NET) during 2016–2017 through 2018–2019 seasons. Patients: Laboratory-confirmed RSV-related hospitalizations in an eight-county catchment area in Tennessee. Methods: Surveillance data from RSV-NET were used to evaluate the population-level burden of healthcare-associated RSV. The incidence of healthcare-associated RSV was determined using the traditional definition (i.e., positive RSV test after hospital day 3) in addition to often under-recognized cases associated with recent post-acute care facility admission or a recent acute care hospitalization for a non-RSV illness in the preceding 7 days. Results: Among the 900 laboratory-confirmed RSV-related hospitalizations, 41 (4.6%) had traditionally defined healthcare-associated RSV. Including patients with a positive RSV test obtained in the first 3 days of hospitalization and who were either transferred to the hospital directly from a post-acute care facility or who were recently discharged from an acute care facility for a non-RSV illness in the preceding 7 days identified an additional 95 cases (10.6% of all RSV-related hospitalizations). Conclusions: RSV is an often under-recognized healthcare-associated infection. Capturing other healthcare exposures that may serve as the initial site of viral transmission may provide more comprehensive estimates of the burden of healthcare-associated RSV and inform improved infection prevention strategies and vaccination efforts.


  • Open Access

    Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults

    by Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman


  • Open Access

    Changes in the cost‐effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults

    by Angela R. Wateska, Mary Patricia Nowalk, Shoroq M. Altawalbeh, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith

    Background: Multiple factors, such as less complex U.S. adult pneumococcal recommendations that could increase vaccination rates, childhood pneumococcal vaccination indirect effects that decrease adult vaccination impact, and increased vaccine hesitancy (particularly in underserved minorities), could diminish the cost‐effectiveness of programs to increase pneumococcal vaccination in older adults. Prior analyses supported the economic favorability of these programs. Methods: A Markov model compared no vaccination and current recommendations (either 20‐valent pneumococcal conjugate vaccine [PCV20] alone or 15‐valent pneumococcal conjugate vaccine plus the 23‐valent pneumococcal polysaccharide vaccine [PCV15/PPSV23]) without or with programs to increase vaccine uptake in Black and non‐Black 65‐year‐old cohorts. Pre‐pandemic population‐ and serotype‐specific pneumococcal disease risk and illness/vaccine costs came from U.S. databases. Program costs were $2.19 per vaccine‐eligible person and increased absolute vaccination likelihood by 7.5%. Delphi panel estimates and trial data informed vaccine effectiveness values. Analyses took a healthcare perspective, discounting at 3%/year over a lifetime time horizon. Results: Uptake programs decreased pneumococcal disease overall. In Black cohorts, PCV20 without program cost $216,805 per quality‐adjusted life year (QALY) gained compared with no vaccination; incremental cost‐effectiveness was $245,546/QALY for PCV20 with program and $425,264/QALY for PCV15/PPSV23 with program. In non‐Black cohorts, all strategies cost >$200,000/QALY gained. When considering the potential indirect effects from childhood vaccination, all strategies became less economically attractive. Increased vaccination with less complex strategies had negligible effects. In probabilistic sensitivity analyses, current recommendations with or without programs were unlikely to be favored at thresholds <$200,000/QALY gained. Conclusion: Current U.S. pneumococcal vaccination recommendations for older adults were unlikely to be economically reasonable with or without programs to increase vaccine uptake. Alternatives to current pneumococcal vaccines that include pneumococcal serotypes associated with adult disease should be considered.